Press release content from Business Wire. The AP news staff was not involved in its creation.
LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA
December 28, 2020 GMT
NEW YORK (BUSINESS WIRE) Dec 28, 2020
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for LORBRENA ® (lorlatinib) as a first-line treatment for people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). The sNDA is based on data from the pivotal CROWN study and is being reviewed by the FDA under its Real-Time Oncology Review (RTOR) pilot program. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in April 2021.
Newswire & Press Release / Kantar Announces Agreement for Sale of Health Division to Cerner - Consulting / Market Research - Kantar newswiretoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswiretoday.com Daily Mail and Mail on Sunday newspapers.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Cerner To Acquire Kantar Health For $375 Mln In Cash
NORTH KANSAS CITY (dpa-AFX) - Cerner Corp. (CERN) said Wednesday that it agreed to acquire Kantar Health, a division of Kantar Group, for $375 million in cash. The merger will create leading data insights and clinical research platform.
Kantar Health is a data, analytics and real-world evidence and commercial research consultancy serving the life science industry.
Cerner expects to close the deal in the first half of 2021, subject to regulatory approval, employee consultations and other conditions. It is not expected to have a material impact on Cerner s earnings in 2021.
Copyright RTT News/dpa-AFX
Cerner Announces Agreement to Acquire Health Division of Kantar
The acquisition will combine industry leading expertise and de-identified real-world data to advance clinical research development
December 16, 2020 Cerner Corporation announced an agreement to acquire Kantar Health, a division of Kantar Group, for $375 million in cash, subject to adjustment. Kantar Health is a leading data, analytics and real-world evidence and commercial research consultancy serving the life science industry. With this acquisition, Cerner plans to harness data to improve the safety, efficiency and efficacy of clinical research across life sciences, pharmaceuticals and health care at large. This acquisition is expected to allow Cerner’s